Showing results (111-120 of 127) with videos related to
Sort By:
Pageof 13
Neurology|May 13, 2021
Primary Progressive Aphasia Associated With <i>GRN</i> Mutations: New Insights Into the Nonamyloid Logopenic VariantDario Saracino, Sophie Ferrieux, Marie Noguès-Lassiaille, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.Nature Communications|January 20, 2023
Integrative genetic analysis illuminates ALS heritability and identifies risk genesSalim Megat, Natalia Mora, Jason Sanogo, et al.Annals of Neurology|January 3, 2021
The Effect of SMN Gene Dosage on ALS Risk and Disease SeverityMatthieu Moisse, Ramona A J Zwamborn, Joke van Vugt, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 13, 2025
Oligogenic structure of amyotrophic lateral sclerosis has genetic testing, counselling and therapeutic implicationsAlfredo Iacoangeli, Allison A Dilliott, Ahmad Al Khleifat, et al.Frontiers in Cellular Neuroscience|March 20, 2023
Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survivalBrett N Adey, Johnathan Cooper-Knock, Ahmad Al Khleifat, et al.Brain : a Journal of Neurology|April 12, 2023
Genetic variability in sporadic amyotrophic lateral sclerosisSien Hilde Van Daele, Matthieu Moisse, Joke J F A van Vugt, et al.Brain : a Journal of Neurology|October 23, 2021
SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degenerationMathieu Barbier, Agnès Camuzat, Khalid El Hachimi, et al.Brain Communications|September 21, 2020
<i>ATXN1</i> repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalizationGijs H P Tazelaar, Steven Boeynaems, Mathias De Decker, et al.Lancet (London, England)|May 12, 2025
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trialGilbert Bensimon, P Nigel Leigh, Timothy Tree, et al.Pageof 13